• Like
  • Comment
  • Favorite

Bellway Heading in the Right Direction But Recovery Pace Might Be Troubling -- Market Talk

Dow Jones2024-10-15

0900 GMT - Bellway's investors are more interested in the housebuilder's outlook for the next year as fiscal 2024 was a tough year and its weakness--pretax profit fell by almost 60%--came as no surprise, Quilter Cheviot analyst Oli Creasey says in a note. Although the direction of travel is positive, the pace of recovery is a little troubling with the company forecasting an 11% increase in volumes next year, Creasey says. Although this is an improvement on fiscal 2024's low base, it is still 22% lower compared to fiscal 2023, he says. Shares are up 6.8% at 3,260 pence. (anthony.orunagoriainoff@dowjones.com)

 

(END) Dow Jones Newswires

October 15, 2024 05:00 ET (09:00 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

empty
No comments yet
errorbox banner

抱歉,当前请求异常(-1)

7x24

  • 20:42

    Medpace Holdings Inc - Amendment No. 7 Extends Revolving Credit Note to March 31, 2026 - SEC Filing

  • 20:42

    Medpace Holdings - Co Units Entered Amendment No. 7 to Loan Documents With PNC Bank - SEC Filing

  • 20:40

    Adverum Biotechnologies Inc - Company Expects to Report at Least One Material Weakness - SEC Filing

  • 20:40

    Adverum Biotechnologies Inc - Some Prior Financial Statements Should No Longer Be Relied Upon - SEC Filing

  • 20:39

    Repare Therapeutics: Lloyd M. Segal Resigned as President, CEO and Director

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email:uservice@ttm.financial